Abstract: The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein2, protein transforming growth factor beta induced protein ig-h3, protein asporin, protein tenascin, protein periostin, protein galectin, protein fibronectin, protein prolargin, protein protein-glutamine gamma-glutamyl transferase 2, protein agrin, protein adipocyte enhancer-binding protein 1, protein annexin A6, protein laminin alpha-2 subunit, proteinlaminin subunit alpha-4, protein mimecan, protein Ras-related protein Rap-2b, protein collagen alpha-1 (XIV) chain, protein collagen alpha-3 (VI) chain, protein latent-transforming growth factor beta binding protein 1, protein V type proton ATPase catalytic subunit A, protein laminin alpha-4 and protein transmembrane protein 62 as a biomarker for pancreatic cancer, or a predisposition thereto.

Abstract: The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein 2, protein transforming growth factor beta induced protein ig-h3, protein adipocyte enhancer-binding protein 1, protein EMILIN1, protein periostin, protein CD97, protein prolargin, protein Thy-1 membrane glycoprotein, protein growth hormone inducible transmembrane protein, protein biglycan, protein EPCAM and protein EMILIN2 as a biomarker for colorectal carcinoma (CRC) liver metastasis, or a predisposition thereto. The invention also relates to ligands directed to the above-mentioned biomarkers, for use in the therapeutic and/or prophylactic treatment of CRC liver metastasis.